A physician-venture capitalist Morgan Cheatham joins Jim Breyer to lead healthcare and AI strategy

Breyer Capital Makes a Bold Bet on the Future of Healthcare and Life Sciences

Breyer Capital has named Morgan Cheatham as Partner and Head of Healthcare and Life Sciences, marking a significant step forward in the firm’s strategy to champion breakthroughs in biomedicine and healthcare AI. Cheatham joins from Bessemer Venture Partners, where he served as Vice President and the youngest Board Director in the firm’s history.

Meet the Polymath VC With a White Coat

Cheatham brings an uncommon perspective to venture capital. He’s a soon-to-be MD from Brown’s Warren Alpert Medical School and a notable published AI researcher who recently earned one of just two spots in the nation’s top-ranked Pediatrics-Genetics program at Harvard/Boston Children’s Hospital. He also serves on the Editorial Team at NEJM AI. As a rare hybrid of physician, informaticist, and investor, Cheatham is uniquely equipped to bridge the traditionally siloed worlds of healthcare delivery and biomedical discovery.

From Bedside to Boardroom: Cheatham’s Journey to Breyer Capital

Cheatham first met legendary investor Jim Breyer a decade ago at Brown University, when Breyer spoke at an entrepreneurship class for which Cheatham was a teaching assistant. “That encounter shaped the arc of my career,” says Cheatham. “It was the first time I’d heard someone articulate a grander vision of how computation and investment could reshape medicine on a non-linear scale. I became fascinated by this vision and decided to pursue venture capital after undergrad. Early in my venture career, Jim and I began co-investing,” said Cheatham. They built a shared thesis around computational medicine and transformative care models.

“It was the first time I’d heard someone articulate a grander vision of how computation and investment could reshape medicine on a non-linear scale.” — Morgan Cheatham, on meeting Jim Breyer

Cheatham went on to become a Vice President at Bessemer Venture Partners, where he led the firm’s healthcare AI thesis and sourced over a dozen early-stage investments, including Abridge and Hinge Health. He also helped incubate and launch a cardiology business and served as Interim CEO at a fast-growing telemedicine company, increasing revenue by 200% in nine months. He was instrumental in Bessemer’s biotech practice and co-founded Decoding Bio. Cheatham also launched initiatives like the Deep Health Seed Program and authored frameworks such as “10 Laws of Healthcare” and “Six Imperatives for AI-First Companies.” He was named to Forbes’ 30 Under 30 list for Venture Capital and honored by the NVCA in 2023.

Breyer Elevates a Strategic Architect for Healthcare’s Next Chapter

At Breyer Capital, Cheatham will lead healthcare and life sciences investing, with a focus on computational methods and precision medicine approaches. His appointment underscores Breyer Capital’s deeper commitment to transformative healthcare innovation at the intersection of AI and biomedicine.

“He brings clinical insight, venture experience, and a sharp eye for transformative science.” — Jim Breyer, on Morgan Cheatham

Jim Breyer’s Trillion-Dollar Track Record

Jim Breyer, Founder and CEO of Breyer Capital, is one of Silicon Valley’s most successful VCs. He was an early investor in over 40 companies that went public or were acquired, including Facebook, where returns exceeded 100x.
Breyer has a strong personal and investment focus on long-term bets in AI, quantum computing, and computational healthcare. He has been named #1 on the Forbes Midas List of Tech’s Top Investors three times and has earned multiple lifetime achievement awards in venture capital.

Not Your Typical Venture Portfolio

Breyer Capital is a global firm backing long-term, idea-driven investments across AI, healthcare, life sciences, consumer tech, and enterprise software. Its portfolio includes companies such as Meta (Facebook), Grammarly, Circle, Epic Games, Legendary Entertainment, Etsy, and Spotify. The firm invests using Breyer’s personal capital alongside select institutional co-investors.

Backing the Boldest Ideas in Biomedicine

Since 2016, Breyer has forged deep ties with research universities like Stanford, Harvard, MIT, UCSF, and UT Austin. In 2025, Breyer Capital partnered with Harvard Medical School’s Department of Biomedical Informatics to support AI-powered precision medicine, reinforcing the firm’s leadership in healthcare innovation.

“The future of medicine will be shaped not just by biology, but by code.”

Breyer and Cheatham: A Visionary Partnership Built on Experience and Expertise

Breyer contributes generational investing experience, while Cheatham offers deep healthcare and AI domain expertise. Their collaboration represents a rare combination of institutional foresight and next-gen perspective.
Breyer Capital’s healthcare portfolio includes Artera, Atropos Health, Cleerly, Iterative Health, OpenEvidence, Slope, and SandboxAQ. The firm continues to focus on reimagining the infrastructure of modern care by backing software-driven platforms addressing clinical needs.

Why Breyer Thinks Medicine’s Next Breakthroughs Will Be Shaped by Code

“We are thrilled to welcome Morgan to the team,” said Jim Breyer. “He brings clinical insight, venture experience, and a sharp eye for transformative science.”
Cheatham added, “Scientific and technological progress is outpacing the evolution of healthcare delivery. I’m excited to invest in the next generation of companies born at the convergence of discovery, clinical need, and institutional change.”
The hire reflects Breyer Capital’s growing conviction that the future of medicine lies in code-driven breakthroughs.